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Tbjectives: The disappointing results of myocardial angiogenic therapy have been
ttributed, in part, to endothelial dysfunction present in patients with coronary
isease. Statins have established proendothelial properties but seem to have dose-
ependent effects on angiogenesis. We investigated the functional and molecular
ffects of high-dose atorvastatin on vascular endothelial growth factor–induced
yocardial angiogenesis in hypercholesterolemic swine.
ethods: Yucatan miniswine (20-30 kg) were fed either a normal (ND group, n  8)
r high-cholesterol diet, with (HC-ATOR group, n  8) or without (HC group, n  8)
torvastatin (3 mg · kg1 · d1), for 13 weeks. Chronic ischemia was induced by
meroid constrictor placement around the circumflex artery, followed 3 weeks later by
erivascular vascular endothelial growth factor administration (2 g over 4 weeks) with
sustained release osmotic pump. Microvessel relaxation responses, myocardial perfu-
ion, and myocardial expression of angiogenic mediators were assessed 4 weeks later.
esults: Hypercholesterolemic swine demonstrated impaired microvessel relaxation
o vascular endothelial growth factor (P  .01 vs ND group) and adenosine
iphosphate (P  .001 vs ND group), which was normalized in the HC-ATOR
roup.Afterperivascularvascular endothelial growth factor administration, collateral-
ependent myocardial perfusion was significantly increased in the ND group but
ecreased in both the HC and HC-ATOR groups (both P  .01 vs the ND group).
he animals in the HC-ATOR group demonstrated increased myocardial expression
f the antiangiogenic protein endostatin and increased Akt phosphorylation without
ignificant changes in Akt and endothelial nitric oxide synthase expression.
onclusions: Atorvastatin treatment reverses hypercholesterolemia-induced endo-
helial dysfunction without appreciable improvements in collateral-dependent myo-
ardial perfusion in response to vascular endothelial growth factor treatment.
ncreased myocardial endostatin expression and chronic Akt activation, associated
ith atorvastatin therapy, might account for the lack of improvement in the angio-
enic response to vascular endothelial growth factor therapy.
lthough growth factor therapy has been demonstrated to result in myocar-
dial angiogenesis in animal models, clinical trials to date have shown
limited benefit in patients. It is becoming increasingly clear that angiogen-sis is a complex process that involves interactions between proangiogenic and
he Journal of Thoracic and Cardiovascular Surgery ● Volume 132, Number 6 1299
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CSPntiangiogenic mediators, a functioning endothelium, and
he extracellular matrix. Growth factors implicated in the
ngiogenic response, like vascular endothelial growth factor
VEGF) and basic fibroblast growth factor (FGF-2), act in
arge part through the activation of tyrosine kinase recep-
ors, leading eventually to the release of nitric oxide
NO).1-3 The presence of endothelial dysfunction caused by
educed NO bioavailability is a common finding in patients
ith coronary artery disease and might contribute to the
imited benefit seen in clinical trials of growth factor
dministration for therapeutic angiogenesis.4 Indeed, the
ritical role played by a functioning endothelium has been
ighlighted in numerous studies by our group, as well as
thers,5,6 in which we demonstrated that hypercholesterol-
mia-induced endothelial dysfunction is associated with a
iminished endogenous and growth factor–induced angio-
enic response to chronic ischemia,7-9 and reversal of en-
othelial dysfunction by L-arginine supplementation (an NO
ubstrate) rescues the impaired angiogenic response.
3-Hydroxy-3-methylglutaryl coenzyme A reductase in-
ibitors (statins) are commonly used in patients with coro-
ary disease and can improve peripheral and coronary
ndothelial dysfunction in these patients.10 Statins can in-
rease NO bioavailability by activating Akt, which subse-
uently leads to endothelial nitric oxide synthase (eNOS)
ctivation,11 as well as through its antioxidant effects.12
owever, in vitro and murine studies have suggested a
iphasic and dose-dependent effect of statins on endothelial
ell proliferation, migration, and apoptosis, which are key
vents in angiogenesis.13,14 We have recently reported an
mpaired endogenous angiogenic response to statins in a
wine model of chronic myocardial ischemia.15 Further-
ore, there is an increased emphasis on high-dose statin
reatment in patients with coronary artery disease.16 The
ims of this study were to evaluate the functional and molec-
lar effects of high-dose atorvastatin on coronary microvascu-
ar function and the angiogenic response to perivascular,
ntramyocardial VEGF therapy in a clinically relevant por-
ine model of hypercholesterolemia-induced endothelial
Abbreviations and Acronyms
ADP  adenosine 5=-diphosphate
ANOVA analysis of variance
eNOS  endothelial nitric oxide synthase
FGF-2  basic fibroblast growth factor
ILM  isotope-labeled microsphere
NO  nitric oxide
SNP  sodium nitroprusside
VEGF  vascular endothelial growth factorysfunction. i
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eneral Experimental Sequence
wenty-four Yucatan miniswine of either sex (Sinclair Research
nc, Colombia, Mo) were used for the studies. After weaning at
weeks of age, animals were divided into 3 groups. The first group
as fed a normal pig diet (ND group, n 8); the second was given
hypercholesterolemic diet (Purina Modified Mini-Pig Grower
iet 5081, Richmond, Ind) consisting of 20% lard, 4% cholesterol,
nd 1.5% sodium cholate (HC group, n  8); and the third
eceived a hypercholesterolemic diet with oral atorvastatin
3 mg · kg1 · d1; Pfizer Inc, New York, NY; HC-ATOR group,
 8) for the duration of the study (total 20 weeks).
All animals underwent an identical experimental protocol in-
olving 3 separate procedures on each animal. Anesthesia was
erformed as reported previously,7 and all animals received hu-
ane care in compliance with the Harvard Medical Area Institu-
ional Animal Care and Use Committee and the National Research
ouncil’s “Guide for the care and use of laboratory animals”
repared by the Institute of Laboratory Animals and published by
he National Institutes of Health (National Institutes of Health
ublication no. 5377-3 1996). Briefly, for all surgical procedures,
nesthesia was induced with ketamine (10 mg/kg administered
ntramuscularly), thiopental (5-10 mg/kg administered intrave-
ously), and thiopental 2.5% and maintained with a gas mixture
f oxygen at 1.5 to 2 L/min and isoflurane at 0.75% to 3.0%.
he animals were intubated and mechanically ventilated at 12
o 20 breaths/min.
The first procedure, performed through a small left anterolateral
horacotomy at 20 weeks of age, consisted of the placement of a
.75-mm ameroid constrictor around the proximal circumflex ar-
ery and the injection of 1.5  107 gold-labeled microspheres into
he left atrium during temporary circumflex coronary occlusion to
ubsequently allow for identification, by means of shadow label-
ng, of the myocardial territory at risk.
The second procedure, also performed through a left anterolat-
ral thoracotomy 3 weeks after ameroid placement, consisted of
.5 107 lutetium microspheres injected in the left atrium to allow
or determination of baseline perfusion after ameroid closure. Left
oronary angiography was performed through an 8F sheath (Cor-
is Corp, Miami, Fla) surgically inserted in the femoral artery by
sing a catheter with the appropriate distal angulation and high
tomic weight contrast (Mallinckrodt Inc, St Louis, Mo) to docu-
ent ameroid closure. After microsphere injection, an osmotic pump
Model 2ML4; Alzet Inc, Cupertino, Calif) containing human recom-
inant VEGF (VEGF165) was used to provide sustained intramyocar-
ial delivery of the growth factor by using a microcatheter implanted
n the ischemic territory. VEGF (2 g) mixed with 50 units of heparin
as delivered as a 2-mL solution over 4 weeks at a rate of 3 L/h in
he ischemic territory, as previously described.9,17
The third procedure was carried out at 27 weeks of age (4 weeks
fter the second procedure and 7 weeks after ameroid placement).
ternotomy was performed, and 1.5 107 samarium microspheres
ere injected into the left atrium. Euthanasia was then performed
ith 10 mL/kg of a saturated KCl solution administered intrave-
ously. Cardiac samples were harvested and snap-frozen for mo-
ecular studies; sectioned, weighed, and refrigerated for myocar-
ial microsphere analyses; and put in 4°C Kreb’s solution for
n vitro assessment of coronary microvascular reactivity. Ameroid
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Ponstrictors were resected along with a segment of circumflex
rtery and examined under low-power magnification to confirm
cclusion.
n Vitro Assessment of Coronary
icrovessel Reactivity
fter cardiac harvest, epicardial coronary arterioles (80 to 150 m
n diameter and 1 to 2 mm in length) originating from branches of
he left anterior descending and circumflex arteries were dissected
rom the surrounding tissue with a dissecting microscope (40
agnification) and examined in isolated organ chambers, as de-
cribed previously.1 The responses to sodium nitroprusside (SNP;
nmol/L to 100 mol/L), an endothelium-independent cyclic
uanosine monophosphate–mediated vasodilator, and adenosine
=-diphosphate (ADP; 1 nmol/L to 10 mol/L), VEGF (1 fmol/L
o 1 nmol/L), and FGF-2 (1 fmol/L to 1 nmol/L), all endothelium-
ependent receptor–mediated vasodilators that act through bio-
vailable NO, were studied after precontraction by 30% to 50% of
he baseline diameter with the thromboxane A2 analog U46619
0.1-1 mol/L). Relaxation responses were defined as the percent-
ge of relaxation of the precontracted diameter, and 6 to 8 vessels
ere examined in each group from the left anterior descending and
ircumflex territories.
ssessment of Myocardial Perfusion
yocardial perfusion was assessed during each procedure with
sotope-labeled microspheres (ILMs; BioPAL, Worcester, Mass)
y using previously reported methods.8 ILMs, 15 m in diameter,
f different isotopic masses were used at each experimental stage.
old-labeled microspheres were injected during temporary cir-
umflex occlusion at the time of ameroid placement to identify
yocardial samples that originated from the circumflex coronary
istribution (those with the lowest count of gold-labeled micro-
pheres). Lutetium-labeled ILMs were used during the second pro-
edure to determine baseline blood flow, and samarium-labeled
LMs were injected during the third procedure. Reference blood
amples were obtained from the femoral artery during the
econd and third procedures. After euthanasia, 10 circumferen-
ial, transmural left ventricular sections were collected for ILM
ssays in each animal, weighed, and dried. Each sample was
xposed to neutron beams, and microsphere densities were
easured in a gamma counter. Adjusted myocardial blood flow,
eflecting changes in lateral myocardial perfusion, was deter-
ined from the 2 myocardial samples that showed the lowest
ount of gold-labeled microspheres by using the following
quations:
rude blood flow (tissue sample)
 (Withdrawal rate [mL ⁄ min] ⁄ Weight [tissue sample])
 (Isotope counts [tissue sample] ⁄ Isotope counts
 [reference blood sample])
djusted blood flow
 Crude blood flow (3rd operation) Crude blood flow at baseline (2nd operation) t
The Journal of Thoracicmmunohistochemistry
yocardial sections from the circumflex territory of animals from
roups ND, HC, and HC-ATOR were stained with anti-platelet/
ndothelial cell adhesion molecule-1 (CD-31) antibody diluted to
:600 (BD Biosciences, San Diego, Calif), as previously de-
cribed.8 The sections were counterstained with methyl green and
xamined for capillary endothelial cell density in a triplicate blinded
ashion from 600  440 m (0.264 mm2) cross-sectional fields
andomly selected from the center of circumflex territories.
estern Blotting
hole-cell lysates were isolated from the homogenized myocar-
ial samples with RIPA buffer (Boston Bioproducts, Worcester,
ass) and centrifuged at 12,000g for 10 minutes at 4°C to separate
oluble from insoluble fractions. Protein concentration was mea-
ured spectrophotometrically at 595-nm wavelength with a DC
rotein assay kit (Bio-Rad, Hercules, Calif ). Forty micrograms of
otal protein was fractionated by 4% to 20% gradient sodium
odecylsulfate polyacrylamide gel electrophoresis (Invitrogen, San
iego, Calif ) and transferred to polyvinylidene difluoride mem-
ranes (Millipore, Bedford, Mass). Each membrane was incubated
ith specific antibodies as follows: anti-eNOS antibody (1:2500;
D Biosciences, San Jose, Calif ), anti-phospho-Akt antibody
1:1000), anti-Akt antibody (1:1000; Cell Signaling, Beverly, Mass),
nti-endostatin antibody (1:1000; Upstate, Chicago, Ill), and anti-
ngiostatin antibody (1:1000; EMD Biosciences, San Diego, Calif ).
hen the membranes were incubated for 1 hour in diluted appro-
riate secondary antibody (Jackson Immunolab, West Grove, Pa).
mmune complexes were visualized with the enhanced chemilu-
inescence detection system (Amersham, Piscataway, NJ). Bands
ere quantified by means of densitometry of radioautograph films.
ata Analysis
ata are reported as means  standard error of the mean.
icrovessel responses are expressed as the percentage relax-
tion of the preconstricted diameter and were analyzed by using
epeated-measures analysis of variance (ANOVA), examining
he relationship between vessel relaxation, log concentration of the
asoactive agent, and the experimental group (Graphpad Prizm
.0; GraphPad, San Diego, Calif ). Subgroup testing was done only
f the ANOVA P value was less than .05. Immunoblots are
xpressed as a ratio of protein to loading band density and were
nalyzed after digitization and quantification of x-ray films with
mageJ 1.33 (National Institutes of Health, Bethesda, Md). Blots
nd ILM data were analyzed with 1-way ANOVAs. Bonferroni
orrections were applied to multiple tests.
esults
nimal Model
hree animals died 1 day after ameroid placement, 1 in each
roup, likely because of arrhythmias. In the HC group 1
dditional animal died at the time of the second operation
ecause of intractable ventricular arrhythmias, and 1 animal
as killed early in the HC-ATOR group because of iliac
rtery thrombosis resulting in severe ischemic limb pain.
Serum cholesterol levels were significantly increased inhe HC group compared with those in the ND group (20.1
and Cardiovascular Surgery ● Volume 132, Number 6 1301
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1
CSP.7 vs 2.3  0.4 mmol/L, P  .001). Atorvastatin treatment
esulted in a 30% reduction in serum cholesterol levels
14.2  1.8 mmol/L, P  .05 vs the HC group). Table 1
epicts the lipid profile of study animals.
oronary Microvessel Reactivity
icrovessel responses are depicted in Figure 1. Coronary
icrovessel relaxation in the hypercholesterolemic ani-
als (HC group) was impaired in response to ADP and
EGF, indicating a marked reduction in bioavailable
O. Atorvastatin supplementation resulted in a normal-
zation of this endothelial dysfunction. Microvessel re-
Figure 1. Coronary microvascular reactivity. Relaxation re
growth factor (VEGF ; A), adenosine 5=-diphosphate (ADP ; B
independent vasodilator sodiumnitroprusside (SNP ; D) in the
after preconstriction with U46619 are shown. *P< .01 versu
ABLE 1. Lipid profiles of study animals
ND group HC group
HC-ATOR
group
otal cholesterol (mmol/L) 2.3 0.4 20.1 1.7 14.2  1.8
riglycerides (mmol/L) 0.10 0.01 0.57 0.09 0.61  0.20
DL (mmol/L) 0.47 0.10 2.15 0.18 2.24  0.32
DL (mmol/L) 1.58 0.25 17.7 1.7 11.65 1.56
D, Normal diet; HC, high-cholesterol diet; HC-ATOR, high-cholesterol diet
upplemented with atorvastatin; HDL, high-density lipoprotein; LDL, low-
ensity lipoprotein.HC, high-cholesterol diet; HC-ATOR, high-cholesterol diet supplem
302 The Journal of Thoracic and Cardiovascular Surgery ● Decaxation in response to FGF-2 was impaired in hypercho-
esterolemic animals (23%  3% vs 47%  4%, P 
001) and recovered only partially with atorvastatin treat-
ent (34%  3%, P  0.06 vs the HC group). Endothe-
ium-independent responses to SNP were preserved in all
roups (P  .67, ANOVA).
yocardial Perfusion
aseline myocardial perfusion of the circumflex territory,
etermined 3 weeks after ameroid placement, was similar
etween groups (0.39  0.06 vs 0.55  0.07 vs 0.51 
.05 mL · min1 · g1, ND group vs HC group vs HC-
TOR group; P  .29, ANOVA). As seen in Figure 2, after
weeks of VEGF treatment, the normocholesterolemic
nimals had a significant increase in circumflex territory
erfusion, whereas the hypercholesterolemic animals dem-
nstrated reduced perfusion. A similar reduction in myocar-
ial perfusion was observed in the circumflex territory of
he atorvastatin-treated animals.
apillary Endothelial Cell Density
igure 3 depicts the results of endothelial cell (CD31) staining.
onsistent with the myocardial perfusion results, the hyper-
holesterolemic animals demonstrated a significant reduction
ses to increasing concentrations of vascular endothelial
sic fibroblast growth factor (FGF-2 ; C), and the endothelium-
mic territory of animals in theND, HC, andHC-ATOR groups
ND group, †P .06 versus the HC group. ND, Normal diet;spon
), ba
ische
s theented with atorvastatin.
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Pn endothelial cell density in the ischemic territory, which was
urther reduced in atorvastatin-treated animals.
estern Blotting
torvastatin-treated animals demonstrated significantly in-
reased Akt phosphorylation, whereas total Akt expression
n the myocardium was similar between groups. Endothelial
OS expression was similar between groups (P  .40,
NOVA; Figure 4, B). Interestingly, myocardial expres-
ion of the antiangiogenic protein endostatin was signifi-
antly increased in the ischemic territory of atorvastatin-
reated animals. Expression of angiostatin was similar
mong groups.
iscussion
n this study swine treated for 20 weeks with a hypercho-
esterolemic diet demonstrated impaired coronary microves-
el relaxation to ADP and VEGF, whereas microvessel
elaxation to SNP was preserved, indicating reduced NO
ioavailability and endothelial dysfunction in these animals.
upplementation with atorvastatin reversed the endothelial
ysfunction. Despite improved endothelial dysfunction,
owever, VEGF treatment did not result in improvements in
erfusion of the collateral-dependent circumflex territory in
torvastatin-treated animals. This was accompanied by re-
uced endothelial cell density, which was decreased in the
C group and further reduced in the HC-ATOR group.
urthermore, atorvastatin treatment was associated with a
ore than 4-fold increase in Akt phosphorylation and a
-fold increase in the expression of the antiangiogenic me-
igure 2. Myocardial perfusion. Baseline-adjusted circumflex terri-
ory myocardial blood flow in normocholesterolemic (ND), hyper-
holesterolemic (HC), and hypercholesterolemic atorvastatin-
reated (HC-ATOR) animals after 4 weeks of vascular endothelial
rowth factor treatment is shown. Adjusted circumflex territory
ow was significantly reduced in the HC and HC-ATOR groups
ompared with in the ND group. *P < .01 versus the ND group.iator endostatin. In summary, this study provides evidence i
The Journal of Thoracicor impaired VEGF-induced myocardial angiogenesis in
esponse to high-dose atorvastatin treatment, despite im-
roved endothelial function in a clinically relevant model of
hronic myocardial ischemia.
The process of new blood vessel formation requires a
omplex interaction between proangiogenic growth factors,
ntiangiogenic mediators, a functioning endothelium, and
he extracellular matrix. Angiogenic growth factors act by
inding to tyrosine kinase receptors and initiating intracel-
ular signaling that eventually leads to the release of NO.2
pecifically, VEGF binds to and activates its receptor,
EGFR2 (KDR), which leads to the activation of phospha-
idylinositol 3 kinase and downstream phosphorylation of
kt (protein kinase B). Akt activation has numerous down-
tream effects, including phosphorylation of the ho-
odimeric eNOS, leading to the release of NO and vaso-
ilation.11 In vitro studies have demonstrated that exposure
o statins leads to a time- and dose-dependent Akt phos-
horylation (ser473).18 In this study we show that statin
reatment leads to an approximately 4-fold increase in Akt
hosphorylation demonstrated in vivo in myocardial tissue.
his chronic Akt activation might interfere with endoge-
ous VEGF signaling, as well as impair the response to
xogenous VEGF administration. Furthermore, recent stud-
igure 3. Endothelial cell density. CD31 endothelial cell density
er high-power field in the ischemic territory is shown. The HC
roup animals had reduced endothelial cell density compared
ith the ND group animals (230  22 vs 355  42 cells/high-
ower field, *P < .01 versus the ND group), which was further
educed in the HC-ATOR group (166  31 cells/high-power field,
P  .09 versus the HC group). ND, Normal diet; HC, high-
holesterol diet; HC-ATOR, high-cholesterol diet supplemented
ith atorvastatin.es have suggested that chronic Akt activation is potentially
and Cardiovascular Surgery ● Volume 132, Number 6 1303
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1
CSPetrimental to the myocardium, particularly in the setting of
schemia-reperfusion injury.19
Another important molecular finding was the increased
xpression of endostatin, a 20-kd fragment of collagen XVIII,
hich has been shown to inhibit endothelial cell proliferation
nd migration, as well as vascular tube formation.20,21 En-
ostatin is also responsible for endothelial cell apoptosis
n vitro22 and can reduce the expression of hypoxia-inducing
actor23 and interfere with VEGF signaling through down-
egulation of VEGF receptor expression.24 Therefore in-
reased myocardial endostatin expression might also help to
xplain the lack of improvement in perfusion observed in
torvastatin-treated animals.
Statins are increasingly being used at higher doses in
atients with coronary artery disease, not only for choles-
erol reduction but also for their many pleiotropic effects.16
mong these pleiotropic effects is their ability to improve
ndothelial function by increasing bioavailable NO. A va-
iety of statins have been shown to improve endothelial
unction in the peripheral circulation, evaluated primarily
Figure 4. Expression of angiogenic mediators. A, Myo
However, Akt phosphorylation was significantly increase
B, Myocardial expression of endothelial nitric oxide synt
of the antiangiogenic protein endostatin was significantl
ND group. ND, Normal diet ; HC, high-cholesterol diet ; HC-Ahrough flow-mediated or acetylcholine-induced dilation of A
304 The Journal of Thoracic and Cardiovascular Surgery ● Deche brachial artery.10 Of the 3 studies that evaluated epicar-
ial coronary vasodilation in response to acetylcholine, 2
howed a benefit25,26 of statins, and 1 did not.27 The effects
f statins on the coronary microcirculation, which plays a
ritical role in angiogenesis and is physiologically distinct
rom large coronary arteries, have not been well studied. In this
tudy we observed that hypercholesterolemia-induced impair-
ents in coronary microvessel relaxation to the endothelium-
ependent vasorelaxants ADP and VEGF were normalized in
he atorvastatin-treated animals. However, FGF-2–mediated
elaxation only improved partially with atorvastatin treat-
ent, and therefore alterations in the downstream FGF-2
ignaling might be related to the lack of improvement in
yocardial perfusion. Lastly, microvessel relaxation in re-
ponse to SNP was preserved in all groups, indicating intact
ascular smooth muscle cell function.
Although the effects of statins on endothelial function
ave been extensively studied, their effects on new vessel
ormation are less clear. Proangiogenic effects of statins
ave been linked to the phosphorylation and activation of
ial Akt expression was similar between groups.
the HC-ATOR group. *P < .05 versus the ND group.
(eNOS) was similar between groups. C, Expression
reased in the HC-ATOR group. *P < .05 versus the
high-cholesterol diet supplemented with atorvastatin.card
d in
hase
y inc
TOR,kt,18 an important mediator of endothelial cell survival
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Pnd an activator of eNOS.11 However, statins have also been
hown to have dose-dependent and cell-specific effects on
EGF expression, VEGF receptor function, and Akt acti-
ation.14,28 In addition, endothelial cell migration, a critical
vent in angiogenesis, has been demonstrated in vitro to be
ffected by statins in a dose-dependent manner, with lower
oses enhancing migration and higher doses inhibiting it.13
urthermore, apoptosis of vascular smooth muscle cells in
esponse to statins has been demonstrated in models of
ascular injury and neointimal formation.29,30 In a clinically
elevant model of chronic myocardial ischemia, we have
emonstrated that high-dose atorvastatin does not lead to
mprovement in perfusion of the collateral-dependent terri-
ory, despite improvements in microvascular function. These
hanges in myocardial perfusion were accompanied by re-
uced endothelial cell density in atorvastatin-treated ani-
als. These seemingly discordant findings of improved mi-
rovessel relaxation and impaired angiogenesis underscore
he complexity of the angiogenic process, which is a func-
ion of various proangiogenic and antiangiogenic influences.
n our model we found that FGF-2 signaling remained
mpaired in the atorvastatin-treated animals. Furthermore,
hronic Akt activation, which might impair VEGF signal-
ng, and increased expression of endostatin might help to
xplain the antiangiogenic effects of atorvastatin.
odel Strengths and Limitations
he swine model of chronic myocardial ischemia has
een used extensively in preclinical studies of growth
actor- and cell-based angiogenic therapy and provides a
eliable and physiologically relevant measure of myocardial
erfusion.9,31,32 The dose and delivery method for VEGF
as chosen based on previous preclinical studies conducted
n our laboratory.5,6,9,17 However, because the molecular
tudies were only performed at a single time point, 7 weeks
fter ameroid placement, it is likely that many of the acute
hanges in angiogenic mediators in response to chronic
schemia and VEGF treatment are not captured in this model.
urthermore, we used only one high dose of atorvastatin and
herefore were not able to evaluate dose-dependent effects.
onclusions
espite significant improvements in hypercholesterolemia-
nduced endothelial dysfunction, high-dose atorvastatin did
ot result in improved collateral-dependent myocardial per-
usion in response to VEGF in a clinically relevant swine
odel of chronic myocardial ischemia. Atorvastatin supple-
entation was associated with increased Akt activation and
ncreased endostatin expression, which might account for
he attenuated angiogenic response. These antiangiogenic
ffects of statins warrant further study in patients with
nd-stage coronary artery disease, who stand to benefit from
ngiogenic therapy.
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